MX2018014366A - Interfaces de proteina. - Google Patents

Interfaces de proteina.

Info

Publication number
MX2018014366A
MX2018014366A MX2018014366A MX2018014366A MX2018014366A MX 2018014366 A MX2018014366 A MX 2018014366A MX 2018014366 A MX2018014366 A MX 2018014366A MX 2018014366 A MX2018014366 A MX 2018014366A MX 2018014366 A MX2018014366 A MX 2018014366A
Authority
MX
Mexico
Prior art keywords
compounds
cells
target
decrease
dna damage
Prior art date
Application number
MX2018014366A
Other languages
English (en)
Spanish (es)
Inventor
Chahwan Charly
Soloveychik Maria
Original Assignee
Synthex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthex Inc filed Critical Synthex Inc
Publication of MX2018014366A publication Critical patent/MX2018014366A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/645—Fungi ; Processes using fungi
    • C12R2001/85—Saccharomyces
    • C12R2001/865—Saccharomyces cerevisiae
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
MX2018014366A 2016-05-27 2017-05-26 Interfaces de proteina. MX2018014366A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662342840P 2016-05-27 2016-05-27
US201662384226P 2016-09-07 2016-09-07
PCT/US2017/034870 WO2017205852A2 (en) 2016-05-27 2017-05-26 Protein interfaces

Publications (1)

Publication Number Publication Date
MX2018014366A true MX2018014366A (es) 2019-04-11

Family

ID=60411842

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018014366A MX2018014366A (es) 2016-05-27 2017-05-26 Interfaces de proteina.
MX2023002591A MX2023002591A (es) 2016-05-27 2018-11-22 Interfaces de proteina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023002591A MX2023002591A (es) 2016-05-27 2018-11-22 Interfaces de proteina.

Country Status (8)

Country Link
US (4) US10188691B2 (enExample)
EP (2) EP4269427A3 (enExample)
JP (3) JP7080878B2 (enExample)
CN (2) CN116217657A (enExample)
AU (4) AU2017271678B2 (enExample)
CA (1) CA3025423A1 (enExample)
MX (2) MX2018014366A (enExample)
WO (1) WO2017205852A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4269427A3 (en) 2016-05-27 2023-11-22 Synthex, Inc. Protein interfaces
GB2584211B (en) 2017-11-16 2023-05-24 Synthex Inc Selective modulation of protein-protein interactions
WO2019104244A1 (en) * 2017-11-22 2019-05-31 Synthex, Inc. Peptides for inhibiting rad51
CN114401730A (zh) * 2019-05-01 2022-04-26 因内特生物制品有限责任公司 免疫调节组合物和方法
JP7773376B2 (ja) 2019-05-15 2025-11-19 シンセックス， インコーポレイテッド タンパク質の選択的分解
JP2023145812A (ja) * 2020-08-17 2023-10-12 国立大学法人東海国立大学機構 人工タンパク質、Ｒａｓ阻害剤及び抗がん剤

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0830459B1 (en) 1995-04-11 2007-01-24 The General Hospital Corporation Reverse two-hybrid systems
US5733726A (en) 1995-06-07 1998-03-31 Emory University Cytotoxicity-based genetic selection system (TOXSEL)
US5925523A (en) 1996-08-23 1999-07-20 President & Fellows Of Harvard College Intraction trap assay, reagents and uses thereof
AU4159697A (en) 1996-08-23 1998-03-06 President And Fellows Of Harvard College Interaction trap assay, reagents and uses thereof
US6037125A (en) 1996-11-05 2000-03-14 Lexicon Genetics Incorporated Disruption of the mammalian RAD51 protein and disruption of proteins that associate with mammalian RAD51 for hindering cell proliferation and/or viability of proliferating cells
CA2417135C (en) 1997-11-19 2005-04-12 Microbia, Inc. Chimeric pre-activated transcription factors
US6303302B1 (en) 1997-11-19 2001-10-16 The Whitehead Institute For Biomedical Research Regulation of fungal gene expression
JP2002505072A (ja) 1997-11-19 2002-02-19 マイクロビア・インコーポレーテッド プレ活性化キメラ転写因子
EP1053347B1 (en) 1998-01-09 2007-02-28 Phylogica Limited Peptide detection method
US6332897B1 (en) 1998-03-27 2001-12-25 Glaxo Wellcome Inc. Assay methods
ES2284245T3 (es) 1998-03-26 2007-11-01 Glaxo Group Limited Metodo para detectar interaccion proteina-proteina.
US6114111A (en) 1998-03-30 2000-09-05 Rigel Pharmaceuticals, Inc. Mammalian protein interaction cloning system
US6316223B1 (en) 1998-03-30 2001-11-13 Rigel Pharmaceuticals, Inc. Mammalian protein interaction cloning system
DE19901008A1 (de) * 1999-01-13 2000-07-20 Deutsches Krebsforsch Peptide zur Inhibierung von HPV E6-Proteinen
AU3733100A (en) 1999-03-09 2000-09-28 Lexicon Genetics Incorporated Compounds that disrupt mammalian rad51 activity
US7270969B2 (en) * 1999-05-05 2007-09-18 Phylogica Limited Methods of constructing and screening diverse expression libraries
ATE458818T1 (de) 1999-06-07 2010-03-15 Tet Systems Holding Gmbh & Co Tet repressor basierte transkriptionale regulatorische proteine
IL148967A0 (en) 1999-10-07 2002-11-10 Hybrigen Inc Adjustable sensitivity, genetic molecular interaction systems, including protein-protein interaction systems for detection and analysis
US6790607B1 (en) 1999-10-07 2004-09-14 Hybrigen, Inc. Adjustable sensitivity, genetic molecular interaction systems, including protein-protein interaction systems for detection and analysis
US20020086840A1 (en) 2000-01-26 2002-07-04 Zarling David A. Use of Rad51 inhibitors for p53 gene therapy
US7105341B2 (en) 2000-03-06 2006-09-12 Rigel Pharmaceuticals. Inc. In vivo production of cyclic peptides
US7252952B2 (en) 2000-03-06 2007-08-07 Rigel Pharmaceuticals, Inc. In vivo production of cyclic peptides for inhibiting protein—protein interaction
US7566765B2 (en) 2000-03-06 2009-07-28 Rigel Pharmaceuticals, Inc. Heterocyclic compounds containing a nine-membered carbon-nitrogen ring
US7378248B2 (en) 2000-03-06 2008-05-27 Rigel Pharmaceuticals, Inc. In vivo production of cyclic peptides for inhibiting protein-protein interaction
AU2001245584B2 (en) 2000-03-08 2007-02-08 Phylogica Limited Improved reverse n-hybrid screening method
EP1268842B1 (en) 2000-03-08 2006-06-21 Phylogica Limited Improved reverse n-hybrid screening method
US20030211495A1 (en) 2000-03-08 2003-11-13 Richard Hopkins Reverse n-hybrid screening method
GB0006572D0 (en) 2000-03-17 2000-05-10 Isis Innovation Novel transcription transactivator protein
AU2001283226A1 (en) 2001-08-09 2003-02-24 Pangene Corporation Methods and compositions for inhibiting rad51
US20030229004A1 (en) 2002-03-20 2003-12-11 Pangene Corporation Modulation of tumor cells using BER inhibitors in combination with a sensitizing agent and DSBR inhibitors
WO2004042064A2 (en) * 2002-11-07 2004-05-21 Imperial College Innovations Limited Disorders of lipid metabolism
JP2004215624A (ja) * 2003-01-17 2004-08-05 Celestar Lexico-Sciences Inc 相互作用インヒビターの検出方法、相互作用インヒビターライブラリーおよびインヒビター検出キット
ITMI20030821A1 (it) * 2003-04-18 2004-10-19 Internat Ct For Genetic En Gineering And Polipeptidi chimerici e loro uso.
US20060003391A1 (en) * 2003-08-11 2006-01-05 Ring Brian Z Reagents and methods for use in cancer diagnosis, classification and therapy
JP2005095613A (ja) 2003-09-04 2005-04-14 Taiyo Parts Kk 昇降装置
CN1905864B (zh) * 2003-12-01 2011-04-06 库多斯药物有限公司 用于治疗癌症的dna损伤修复抑制剂
JPWO2005095613A1 (ja) 2004-03-30 2008-02-21 ジェノミディア株式会社 Ｒａｄ５１の発現抑制剤、該発現抑制剤を有効成分として含む医薬、及びその使用
EP1810028A2 (en) 2004-10-14 2007-07-25 Rigel Pharmaceuticals, Inc. Heterocyclic inhibitors of ires-mediated translation and methods of use thereof
PT2099442E (pt) 2006-12-26 2015-02-10 Pharmacyclics Inc Métodos de utilização de inibidores de histona desacetilase e monitorização de biomarcadores em terapia de combinação
US8759089B2 (en) 2007-02-06 2014-06-24 Geneprotech, Inc. Methods and systems for high homologous recombination (“HR”) targeting efficiency
US7892823B2 (en) 2007-02-06 2011-02-22 Geneprotech, Inc. Methods and systems for high homologous recombination (“HR”) targeting efficiency
US8105493B2 (en) 2007-06-29 2012-01-31 Jnc Corporation Aggregation and dispersion methods of magnetic particles, separation and detection methods using the same and detection kit
WO2009018219A2 (en) 2007-07-28 2009-02-05 University Of Chicago Methods and compositions for modulating rad51 and homologous recombination
US9273100B2 (en) 2007-11-09 2016-03-01 Board Of Trustees Of Michigan State University Use of Galerina marginata genes and proteins for peptide production
US9518097B2 (en) 2007-11-09 2016-12-13 Board Of Trustees Of Michigan State University Identification and use of genes encoding amatoxin and phallotoxin
US9150897B2 (en) 2010-08-06 2015-10-06 The Regents Of The University Of California Expression and purification of fusion protein with multiple MBP tags
US9249410B2 (en) 2010-12-15 2016-02-02 The Johns Hopkins University Two-hybrid based screen to identify disruptive residues at multiple protein interfaces
JP2014527036A (ja) * 2011-06-27 2014-10-09 ザ ジャクソン ラボラトリー 癌および自己免疫疾患の処置のための方法および組成物
US10912761B2 (en) 2012-11-30 2021-02-09 The University Of Chicago Methods and compositions involving RAD51 inhibitors
US20170014360A1 (en) 2014-03-10 2017-01-19 The University Of Chicago Methods of treating cancer using rad51 small molecule stimulators
WO2016140971A1 (en) 2015-03-02 2016-09-09 The Regents Of The University Of California Novel rad51 inhibitors and uses thereof
EP4269427A3 (en) 2016-05-27 2023-11-22 Synthex, Inc. Protein interfaces
GB2584211B (en) 2017-11-16 2023-05-24 Synthex Inc Selective modulation of protein-protein interactions

Also Published As

Publication number Publication date
EP3463414A4 (en) 2019-10-23
US10188691B2 (en) 2019-01-29
WO2017205852A2 (en) 2017-11-30
EP3463414A2 (en) 2019-04-10
JP2019527066A (ja) 2019-09-26
US20190216879A1 (en) 2019-07-18
AU2022259709A1 (en) 2022-11-24
MX2023002591A (es) 2024-02-08
JP7479421B2 (ja) 2024-05-08
CN109562138B (zh) 2023-03-21
US20250177474A1 (en) 2025-06-05
EP4269427A2 (en) 2023-11-01
CN116217657A (zh) 2023-06-06
BR112018074472A2 (pt) 2019-03-19
AU2024204362A1 (en) 2024-07-11
CN109562138A (zh) 2019-04-02
EP3463414B1 (en) 2023-09-13
JP2022119883A (ja) 2022-08-17
AU2021205010B2 (en) 2022-08-11
AU2021205010A1 (en) 2021-08-05
CA3025423A1 (en) 2017-11-30
US12214008B2 (en) 2025-02-04
WO2017205852A3 (en) 2018-01-25
EP4269427A3 (en) 2023-11-22
AU2017271678A1 (en) 2018-12-13
EP3463414C0 (en) 2023-09-13
US20210252100A1 (en) 2021-08-19
AU2017271678B2 (en) 2021-05-06
US20170368132A1 (en) 2017-12-28
JP2024099695A (ja) 2024-07-25
JP7080878B2 (ja) 2022-06-06

Similar Documents

Publication Publication Date Title
MX2023002591A (es) Interfaces de proteina.
CY1123957T1 (el) Θεραπεια συνδυασμου για καρκινο
CY1125476T1 (el) Καινοφανης αμφιειδικη μορφη καταλληλη για χρηση σε διερευνητικο ελεγχο υψηλης αποδοσης
CY1122948T1 (el) 1η-πυρρολο[2,3-c]πυριδιν-7(6η)-ονες και πυραζολο[3,4-c]πυριδιν-7(6η)-ονες ως αναστολεις των βετ πρωτεϊνων
EP4219744A3 (en) Methods of preparing nucleic acids for sequencing
MX2023011785A (es) Metodos y composiciones para produccion de proteina de clara de huevo.
AU2019268074A1 (en) Methods for treating hepcidin-mediated disorders
PH12021552158A1 (en) Antibodies to icos
PH12017500022A1 (en) Carrier-antibody compositions and methods of making and using the same
EA201592005A1 (ru) Бициклические гетероциклы в качестве ингибиторов fgfr
BR112016016916A2 (pt) método de tratamento de angiodema hereditário (hae)
PH12021550394A1 (en) Bicyclic heterocycles as fgfr4 inhibitors
CR20170282A (es) Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cáncer
EA201790505A1 (ru) Соединение, нацеленое на ил-23а и фно-альфа, и его применение
MX2017007196A (es) Fibroblastos de embrion de pollo inmortalizados.
HK1245080A1 (zh) 自然杀伤细胞的方法和组合物
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
AU2016263598A8 (en) Methods and kits for treating depression
MX375524B (es) Anticuerpos anti-axl.
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MX393818B (es) Terapias de combinación para el tratamiento de cáncer.
MX2018005348A (es) Composiciones y metodos para transduccion de tumores.
MX2017001263A (es) Fragmentos de anticuerpos radiomarcados para usarse en la prevencion y/o tratamiento de cancer.
MX2021001418A (es) Produccion de proteinas heteromultimericas usando celulas de mamifero.
MX374415B (es) Composiciones y métodos para identificar un riesgo de cáncer en un sujeto.